Kidney Tissue Printing Enters Pre-Clinical Validation: How OrganFabric's Bio-Ink Technology Breaks the Vascularization Bottleneck

On August 10, 2028, bioprinting company OrganFabric published a paper in Nature Biotechnology reporting that its 3D-printed kidney tissue survived in a pig for 14 days and produced urine. This is the first time functional vascularized tissue from a bioprinter has achieved long-term survival outside the body.

OrganFabric's breakthrough addresses organ printing's core challenge: vascularization. Previous 3D-printed organ tissues could replicate cell arrangements but lacked vascular networks, causing interior cells to die from lack of nutrients.

OrganFabric's solution is the "sacrificial template method": first printing a vascular network template with dissolvable hydrogel, then seeding kidney cells around the template, and finally dissolving the template to leave hollow vascular channels. Once these channels connect with host vasculature, blood can flow into the printed tissue.

OrganFabric's CEO revealed that the company plans to initiate human clinical trials in 2029, starting with smaller kidney tissue patches, with the goal of providing transitional treatment for patients awaiting kidney transplants.